Atmosphere-ph.ru

Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Телефон издательства

Лечебное дело
2016 / N 4

Новая тенденция в лечении остеопороза бисфосфонатами – лекарственные каникулы: для кого, когда и как долго?
О.М. Лесняк, Л.А. Марченкова, Е.В. Макарова

1. Nguyen T.V., Center J.R., Eisman J.A. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004; 180(5 Suppl): S18–22.
2. Kanis J.A., Borgstrom F., Zethraeus N., Johnell O., Oden A., Jönsson B. Intervention thresholds for osteoporosis in the UK. Bone 2005; 36(1): 22–32.
3. Kanis J.A., Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int 2005; 16(3): 229–238.
4. Friedman P.A. Agents affecting mineral ion homeostasis and bone turnover. In: Brunton L.L., Lazo J.S., Parker K.L., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill 2006; 1647–1678.
5. Seeman E., Delmas P.D., Hanley D.A., Sellmeyer D., Cheung A.M., Shane E., Kearns A., Thomas T., Boyd S.K., Boutroy S., Bogado C., Majumdar S., Fan M., Libanati C., Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25(8):1886–1894.
6. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001; 29(2): 185–191.
7. Manolagas S.C. Birth and death of bone cell: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21(2): 115–137.
8. Остеопороз. Диагностика и лечение. Под ред. Стоувэлла Д.В. Пер. с англ. под ред. Лесняк О.М. М.: ГЭОТАР-Медиа 2015; 228с.
9. Rodan G, Reszka A., Golub E., Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004; 20(8): 1291–1300.
10. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19(6): 733–759.
11. Green J.R., Müller K., Jaeggi K.A. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9(5): 745–751.
12. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R., HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809–1822.
13. Марченкова Л.А., Древаль А.В., Бахарев И.В. Эффективность и переносимость резокластина ФC (5 мг) при лечении остеопороза: ретроспективный анализ клинического опыта применения препарата в России. Остеопороз и остеопатии. 2014; 3: 22–26.
14. Tower R.J., Campbell G.M., Müller M., Glüer C.C., Tiwari S. Utilizing time-lapse micro-CT-correlated bisphosphonate binding kinetics and soft tissue-derived input functions to differentiate site-specific changes in bone metabolism in vivo. Bone 2015; 74: 171–181.
15. Watts N.B., Chines A., Olszynski W.P., McKeever C.D., McClung M.R., Zhou X., Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19(3): 365–372.
16. Black D.M., Schwartz A.V., Ensrud K.E., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., Satterfield S., Wallace R.B., Bauer D.C., Palermo L., Wehren L.E., Lombardi A., Santora A.C., Cummings S.R.; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927–2938.
17. Black D.M., Reid I.R., Cauley J.A., Cosman F., Leung P.C., Lakatos P., Lippuner K., Cummings S.R., Hue T.F., Mukhopadhyay A., Tan M., Aftring R.P., Eastell R. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015; 30(5): 934–944.
18. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. September 9, 2011. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958. Accessed December 6, 2016.
19. Rizzoli R., Reginster J.Y. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011; 4(5): 593–604.
20. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., Hawker G.A., Gunraj N., Austin P.C., Whelan D.B., Weiler P.J., Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305(8): 783–78.
21. Dell R.M., Adams A.L., Greene D.F., Funahashi T.T., Silverman S.L., Eisemon E.O., Zhou H., Burchette R.J., Ott S.M. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27(12): 2544–2550.
22. Schilcher J., Koeppen V., Aspenberg P., Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014; 371(10): 974–976.
23. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., Gagel RF., Gilsanz V., Guise T., Koka S., McCauley L.K., McGowan J., McKee M.D., Mohla S., Pendrys D.G., Raisz L.G., Ruggiero S.L., Shafer D.M., Shum L., Silverman S.L., Van Poznak C.H., Watts N., Woo S.B., Shane E. American society for bone and mineral research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479–1491.
24. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., O’Ryan F. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw–2014 Update. https://www.researchgate.net/publication/266561211_American_Association_of_Oral_and_Maxillofacial_Surgeons_Position_Paper_on_Medication-Related_Osteonecrosis_of_the_Jaw-2014_ Update Accessed December, 06, 2016.
25. Lo J.C., O’Ryan F.S., Gordon N.P., Yang J., Hui R.L., Martin D., Hutchinson M., Lathon P.V., Sanchez G., Silver P., Chandra M., McCloskey C.A., Staffa J.A., Willy M., Selby J.V., Go A.S.: Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68(2): 243–253.
26. Black D.M., Schwartz A.V., Ensrud K.E., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., Satterfield S., Wallace R.B., Bauer D.C., Palermo L., Wehren L.E., Lombardi A., Santora A.C., Cummings S.R.; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927–2938.
27. Watts N.B., Chines A., Olszynski W.P., McKeever C.D., McClung M.R., Zhou X., Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19(3): 365–372.
28. Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F., Cummings S.R., Hue T.F., Lippuner K., Lakatos P., Leung P.C., Man Z., Martinez R.L., Tan M., Ruzycky M.E., Su G., Eastell R. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 2012; 27(2): 243–254.
29. Xu L.H., Adams-Huet B., Poindexter J.R., Maalouf N.M. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Osteoporos Int 2016; 27(5): 1701–1708.
30. Watts N.B. Long-term risks of bisphosphonate therapy. Arq Bras Endocrinol Metabol 2014 ;58(5): 523–529.
31. Eiken P., Vestergaard P. Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int 2016; 27(1): 1–12.
32. Chiha M., Myers L.E., Ball C.A., Sinacore J.M., Camacho P.M. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting. Endocr Pract 2013; 19(6): 989–994.
33. Tower R.J., Campbell G.M., Müller M., Glüer C.C., Tiwari S. Utilizing time-lapse micro-CT-correlated bisphosphonate binding kinetics and soft tissue-derived input functions to differentiate site-specific changes in bone metabolism in vivo. Bone 2015; 74: 171–181.
34. Kostoff M.D., Saseen J.J., Borgelt L.M. Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy. Int J Womens Health 2014; 6: 423–428.
35. Vestergaard P., Fischer L., Mele M., Mosekilde L., Christiansen P. Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int 2011; 88(4): 255–262.
36. Dreyfuss J.H. Oral bisphosphonate use associated with a decreased risk of breast cancer. CA Cancer J Clin 2010; 60(3): 343–344.
37. Chlebowski R.T., Chen Z., Cauley J.A., Anderson G., Rodabough R.J., McTiernan A., Lane D.S., Manson J.E., Snetselaar L., Yasmeen S., O’Sullivan M.J., Safford M., Hendrix S.L., Wallace R.B. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010; 28(22): 3582–3590.
38. Rennert G., Pinchev M., Rennert H.S. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010; 28(22): 3577–3581.
39. Rennert G., Pinchev M., Rennert H.S., Gruber S.B. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011; 29(9): 1146–1150.
40. Abrahamsen B., Pazianas M., Eiken P., Russell R.G., Eastell R. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012; 27(3): 679–686.
41. Steinbuch M., D’Agostino R.B., Mandel J.S., Gabrielson E., McClung M.R., Stemhagen A., Hofman A. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 2002; 35(3): 320–326.
42. Wolfe F., Bolster M.B., O’Connor C.M., Michaud K., Lyles K.W., Colón-Emeric C.S. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res 2013; 28(5): 984–991.
43. Grey A., Bolland M.J. The effect of treatments for osteoporosis on mortality. Osteoporos Int 2013; 24(1): 1–6.
44. Diab D.L., Watts N.B. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis 2013 5(3): 107–111.
45. Osteoporosis Drug Holiday Guidelines for GPs. http://barnsleybest.nhs.sitekit.net/clinical-support/medicines/prescribing-guidelines/Osteoporosis%20drug%20holiday%20guidelines.pdf Accessed December, 06, 2016.

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]